Serum Proteome Profiles in Cats with Chronic Enteropathies

Overview

Journal J Vet Intern Med

Specialties General Medicine
Veterinary Medicine

Date 2023 Jun 6

PMID 37279179

Authors

Jane Yu

Lara Boland

Melissa Catt

Leah Puk

Nadia Wong

Mark Krockenberger

Peter Bennett

Craig Ruaux

Valerie C Wasinger

Affiliations

Soon will be listed here.

Abstract

Background: Serum protein biomarkers are used to diagnose, monitor treatment response, and to differentiate various forms of chronic enteropathies (CE) in humans. The utility of liquid biopsy proteomic approaches has not been examined in cats.

Hypothesis/objectives: To explore the serum proteome in cats to identify markers differentiating healthy cats from cats with CE.

Animals: Ten cats with CE with signs of gastrointestinal disease of at least 3 weeks duration, and biopsy-confirmed diagnoses, with or without treatment and 19 healthy cats were included.

Methods: Cross-sectional, multicenter, exploratory study with cases recruited from 3 veterinary hospitals between May 2019 and November 2020. Serum samples were analyzed and evaluated using mass spectrometry-based proteomic techniques.

Results: Twenty-six proteins were significantly (P < .02, ≥5-fold change in abundance) differentially expressed between cats with CE and controls. Thrombospondin-1 (THBS1) was identified with >50-fold increase in abundance in cats with CE (P < 0.001) compared to healthy cats.

Conclusions And Clinical Importance: Damage to the gut lining released marker proteins of chronic inflammation that were detectable in serum samples of cats. This early-stage exploratory study strongly supports THBS1 as a candidate biomarker for chronic inflammatory enteropathy in cats.

Citing Articles

Changes in Serum Proteins in Cats with Obesity: A Proteomic Approach.

Canadas-Vidal E, Munoz-Prieto A, Resetar Maslov D, Rubic I, Gonzalez-Sanchez J, Garcia-Martinez J Animals (Basel). 2025; 15(1.

PMID: 39795034 PMC: 11718836. DOI: 10.3390/ani15010091.

Analysis of serum peptidome profiles of non-metastatic and metastatic feline mammary carcinoma using liquid chromatography-tandem mass spectrometry.

Paphussaro W, Roytrakul S, Phaonakrop N, Buthasane W, Rungsipipat A, Tharasanit T BMC Vet Res. 2024; 20(1):280.

PMID: 38951817 PMC: 11218297. DOI: 10.1186/s12917-024-04148-y.

Serum proteome profiles in cats with chronic enteropathies.

Yu J, Boland L, Catt M, Puk L, Wong N, Krockenberger M J Vet Intern Med. 2023; 37(4):1358-1367.

PMID: 37279179 PMC: 10365053. DOI: 10.1111/jvim.16743.

References

Zheng J, Wei R, Wang Z, Zhu T, Ruan H, Wei X . Serum proteomics analysis of feline mammary carcinoma based on label-free and PRM techniques. J Vet Sci. 2020; 21(3):e45. PMC: 7263907. DOI: 10.4142/jvs.2020.21.e45. View

Ekdahl K, Persson B, Mohlin C, Sandholm K, Skattum L, Nilsson B . Interpretation of Serological Complement Biomarkers in Disease. Front Immunol. 2018; 9:2237. PMC: 6207586. DOI: 10.3389/fimmu.2018.02237. View

Shores D, Binion D, Freeman B, Baker P . New insights into the role of fatty acids in the pathogenesis and resolution of inflammatory bowel disease. Inflamm Bowel Dis. 2011; 17(10):2192-204. PMC: 4100336. DOI: 10.1002/ibd.21560. View

Derkacz A, Olczyk P, Olczyk K, Komosinska-Vassev K . The Role of Extracellular Matrix Components in Inflammatory Bowel Diseases. J Clin Med. 2021; 10(5). PMC: 7962650. DOI: 10.3390/jcm10051122. View

Assadsangabi A, Evans C, Corfe B, Lobo A . Application of Proteomics to Inflammatory Bowel Disease Research: Current Status and Future Perspectives. Gastroenterol Res Pract. 2019; 2019:1426954. PMC: 6350533. DOI: 10.1155/2019/1426954. View

Petrey A, de la Motte C . The extracellular matrix in IBD: a dynamic mediator of inflammation. Curr Opin Gastroenterol. 2017; 33(4):234-238. PMC: 5562400. DOI: 10.1097/MOG.0000000000000368. View

Lopez-Dee Z, Pidcock K, Gutierrez L . Thrombospondin-1: multiple paths to inflammation. Mediators Inflamm. 2011; 2011:296069. PMC: 3134184. DOI: 10.1155/2011/296069. View

Tonge R, Shaw J, Middleton B, Rowlinson R, Rayner S, Young J . Validation and development of fluorescence two-dimensional differential gel electrophoresis proteomics technology. Proteomics. 2001; 1(3):377-96. DOI: 10.1002/1615-9861(200103)1:3<377::AID-PROT377>3.0.CO;2-6. View

Shen C, Wang Z, Shankar G, Zhang X, Li L . A hierarchical statistical model to assess the confidence of peptides and proteins inferred from tandem mass spectrometry. Bioinformatics. 2007; 24(2):202-8. DOI: 10.1093/bioinformatics/btm555. View

10.

Kalla R, Adams A, Bergemalm D, Vatn S, Kennedy N, Ricanek P . Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease. J Crohns Colitis. 2020; 15(5):699-708. PMC: 8095384. DOI: 10.1093/ecco-jcc/jjaa230. View

11.

Soomro S, Venkateswaran S, Vanarsa K, Kharboutli M, Nidhi M, Susarla R . Predicting disease course in ulcerative colitis using stool proteins identified through an aptamer-based screen. Nat Commun. 2021; 12(1):3989. PMC: 8239008. DOI: 10.1038/s41467-021-24235-0. View

12.

Brazzell J, Borjesson D . Evaluation of plasma antithrombin activity and D-dimer concentration in populations of healthy cats, clinically ill cats, and cats with cardiomyopathy. Vet Clin Pathol. 2007; 36(1):79-84. DOI: 10.1111/j.1939-165x.2007.tb00186.x. View

13.

Yoshida H, Granger D . Inflammatory bowel disease: a paradigm for the link between coagulation and inflammation. Inflamm Bowel Dis. 2009; 15(8):1245-55. PMC: 2713811. DOI: 10.1002/ibd.20896. View

14.

Marsilio S . Feline chronic enteropathy. J Small Anim Pract. 2021; 62(6):409-419. DOI: 10.1111/jsap.13332. View

15.

Kuznetsov N, Zargari A, Gielen A, von Stein O, Musch E, Befrits R . Biomarkers can predict potential clinical responders to DIMS0150 a toll-like receptor 9 agonist in ulcerative colitis patients. BMC Gastroenterol. 2014; 14:79. PMC: 4005617. DOI: 10.1186/1471-230X-14-79. View

16.

Snel B, Lehmann G, Bork P, Huynen M . STRING: a web-server to retrieve and display the repeatedly occurring neighbourhood of a gene. Nucleic Acids Res. 2000; 28(18):3442-4. PMC: 110752. DOI: 10.1093/nar/28.18.3442. View

17.

Jain U, Otley A, Van Limbergen J, Stadnyk A . The complement system in inflammatory bowel disease. Inflamm Bowel Dis. 2014; 20(9):1628-37. DOI: 10.1097/MIB.0000000000000056. View

18.

Rusk A, McKeegan E, Haviv F, Majest S, Henkin J, Khanna C . Preclinical evaluation of antiangiogenic thrombospondin-1 peptide mimetics, ABT-526 and ABT-510, in companion dogs with naturally occurring cancers. Clin Cancer Res. 2006; 12(24):7444-55. DOI: 10.1158/1078-0432.CCR-06-0109. View

19.

Barclay J, Petersons C, Keshvari S, Sorbello J, Mangelsdorf B, Thompson C . Thrombospondin-1 is a glucocorticoid responsive protein in humans. Eur J Endocrinol. 2015; 174(2):193-201. DOI: 10.1530/EJE-15-0964. View

20.

Norsworthy G, Estep J, Hollinger C, Steiner J, Lavallee J, Gassler L . Prevalence and underlying causes of histologic abnormalities in cats suspected to have chronic small bowel disease: 300 cases (2008-2013). J Am Vet Med Assoc. 2015; 247(6):629-35. DOI: 10.2460/javma.247.6.629. View